

# InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103 Irvine, CA 92618

## **Technical Data Sheet**

Biotinylated Human CD137/4-1BB/TNFRSF9 (C-Fc-Avi)

Catalog Number: 808703, 808704

Size: 25 ug, 100 ug

Target Name: TNFRSF9, 4-1BB, CD137

Regulatory Status: RUO

### **Product Details**

Application: ELISA, BLI Format: Liquid, Biotinylated Expression Host: CHO

Species: Human

Sources: Recombinant Human CD137/4-1BB Protein (Leu24-Gln186) with C-terminus Fc-Avi-tag is

expressed in CHO cell. This protein was site-specifically labeled with Biotin by BirA ligase.

Accession Number: Q07011

Molecular Weight: The protein has a predicted molecular weight of 45.6 kDa. Under DTT-reducing

conditions, it migrates at approximately 55-60 kDa on SDS-PAGE.

Affinity Tag: C-Fc-Avi

Purity: >95% based on SDS-PAGE under reducing condition

Formulation: 1xPBS buffer, pH7.4, 0.22 µm filtered

Endotoxin level: Not tested

Protein Concentration: 25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a

lot-specific concentration.

**Storage and Handling:** Briefly centrifuge the vial upon receipt. An unopened vial can be stored at  $4^{\circ}$ C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22  $\mu$ m-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at <=  $-70^{\circ}$ C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.

### **Background Information**

CD137 (4-1BB) is a co-stimulatory glycoprotein from the tumor necrosis factor (TNF) receptor superfamily, expressed on activated CD4+ and CD8+ T cells. It binds to its ligand, 4-1BBL, found on antigen-presenting cells like macrophages and activated B cells. The interaction between CD137 and 4-1BBL triggers signaling through tumor necrosis factor receptor-associated factors (TRAFs), activating pathways like NF-kappaB and cytokine production. This process promotes T cell activation, proliferation, and immune responses, as well as monocyte and B-cell activation. CD137 and 4-1BBL are present in various human tumors, suggesting they may influence tumor progression. Crosslinking CD137 has shown promise in enhancing anti-tumor immunity in preclinical models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials. Additionally, soluble CD137 (sCD137) can antagonize the membrane-bound form's function, reducing T cell




proliferation and IL-2 secretion.


## InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103 Irvine, CA 92618

### **Product Data**



Human CD137/4-1BB Protein (C-Fc-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under non-reducing (P–) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of the CD137 protein exceeds 90%.



Biotinylated Human CD137/4-IBB (C-Fc-Avi) is coated at 2ug/mL (200ng/well). Human 4-BB Ligand (N-His, catalog 606401) can bind Biotinylated Human CD137/4-IBB (C-Fc-Avi) in dose-dependent manner with the ED50 of 2-10 ng/mL